RedHill Biopharma Ltd. (RDHL) Form 424B5 — Jun 29, 2026
RedHill Biopharma has filed a prospectus supplement to increase the capacity of its At-The-Market (ATM) offering agreement. The company is now authorized to sell up to an additional $2.128 million in American Depositary Shares through its sales agent, H.C. Wainwright & Co. This increase follows the sale of approximately $49,690 in shares over the preceding 12-month period.
Key figures
- Gross Proceeds
- $2,128,000
- Public float
- $6,534,464
- Previous ads sold
- 54,954
- Previous sales proceeds
- $49,690
Price after filing
1 day: -1.8%7 days: -8.2%30 days: -15.1%
Close on the filing date to close N calendar days later (from $0.86). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.